Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 24;14(23):5773.
doi: 10.3390/cancers14235773.

Current Radiotherapy Considerations for Nasopharyngeal Carcinoma

Wai Tong Ng  1   2 , James C H Chow  3 , Jonathan J Beitler  4 , June Corry  5 , William Mendenhall  6 , Anne W M Lee  1 , K Thomas Robbins  7 , Sandra Nuyts  8 , Nabil F Saba  9 , Robert Smee  10 , William A Stokes  11 , Primož Strojan  12 , Alfio Ferlito  13
Affiliations
Review

Current Radiotherapy Considerations for Nasopharyngeal Carcinoma

Wai Tong Ng et al. Cancers (Basel). .

Abstract

Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma (NPC). Successful curative treatment requires optimal radiotherapy planning and precise beam delivery that maximizes locoregional control while minimizing treatment-related side effects. In this article, we highlight considerations in target delineation, radiation dose, and the adoption of technological advances with the aim of optimizing the benefits of radiotherapy in NPC patients.

Keywords: adaptive planning; artificial intelligence; nasopharyngeal cancer; particle therapy; radiotherapy; target delineation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Au K.H., Ngan R.K.C., Ng A.W.Y., Poon D.M.C., Ng W.T., Yuen K.T., Lee V.H.F., Tung S.Y., Chan A.T.C., Sze H.C.K., et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) Oral Oncol. 2018;77:16–21. doi: 10.1016/j.oraloncology.2017.12.004. - DOI - PubMed
    1. Liang S.-B., Wang Y., Chun-Yan C., He S.-S., Yang X.-L., Liu L.-Z., Cui C.-Y., Chen Y., Fu L.-W. Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. J. Cancer. 2017;8:3718–3724. doi: 10.7150/jca.20351. - DOI - PMC - PubMed
    1. Lee A.W., Ng W.T., Pan J.J., Chiang C.-L., Poh S.S., Choi H.C., Ahn Y.C., AlHussain H., Corry J., Grau C., et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2019;105:567–580. doi: 10.1016/j.ijrobp.2019.06.2540. - DOI - PubMed
    1. Lee A.W., Ng W.T., Pan J.J., Poh S.S., Ahn Y.C., AlHussain H., Corry J., Grau C., Grégoire V., Harrington K.J., et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother. Oncol. 2018;126:25–36. doi: 10.1016/j.radonc.2017.10.032. - DOI - PubMed
    1. Zhang S., Yang S., Xu P., Xu Y., Zhou G., Ou X., Wu R., Lan M., Fontanarosa D., Dowling J., et al. Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. Front. Oncol. 2020;10:1572. doi: 10.3389/fonc.2020.01572. - DOI - PMC - PubMed

LinkOut - more resources